The Women's Tennis Association implemented mandatory genetic testing for all players competing in WTA tournaments, effective July 21, 2026, making professional women's tennis the first major women's sports league in the world to require genetic testing as a condition of competition. The policy requires a one-time screening for the SRY gene, which plays a role in determining biological sex during fetal development, and is designed to enforce the WTA's updated Women's Eligibility Policy based on biological sex.
The policy was announced in mid-July and began taking effect this week, drawing immediate and pointed responses from The 19th, which published a detailed analysis of who is most likely to be affected, from STAT News, from bioethicists, and from physicians specializing in genetics and sports medicine. Their concern is not hypothetical: the policy has the greatest potential to affect intersex cisgender women, not transgender women, and many of the people most at risk do not know they are intersex.
Why This Matters
The SRY gene is located on the Y chromosome and triggers male sex development during fetal development in most people. However, sex biology is more complex than a single gene. Women with Swyer syndrome, for example, have XY chromosomes including the SRY gene, but their bodies did not respond to the male hormone signals during development, and they were born with female anatomy, live as women, and have always been recognized as women in every context other than a genetic test result. Women with Complete Androgen Insensitivity Syndrome follow a similar pattern.
According to The 19th's reporting, these conditions and others like them represent a range of intersex variations that could cause a woman to fail the SRY gene test through no fault of sex or gender identity, simply because of how her chromosomes and hormones interacted during fetal development. Some estimates suggest that intersex variations of various kinds are present in approximately 1.7 percent of the population, though definitions vary. Many people with these conditions do not discover them unless specifically tested.
The WTA policy includes exceptions for intersex individuals. But those exceptions require further testing, medical records, and potentially physician involvement, imposing a burden of proof on women who have lived their entire lives as women and who never chose to submit to genetic scrutiny as a condition of playing tennis.
What We Know So Far
The WTA's updated Women's Eligibility Policy was approved by the WTA Board and came into effect on July 21, 2026. The policy describes its purpose as preserving the integrity of women's professional tennis and maintaining fair competition conditions. The SRY gene screening is described as a one-time required process, conducted with confidentiality and data privacy safeguards. Players who test positive for the SRY gene would be required to undergo additional testing and submit medical documentation before being permitted to compete.
STAT News reported that the WTA is the first major women's professional sports organization to implement this kind of blanket genetic testing requirement. Other sporting bodies, including World Athletics, implemented SRY gene testing beginning in 2025, but the WTA's policy is notable for applying to all players rather than only those raising eligibility questions.
The Washington Post reported that the testing will also be a requirement for competing at the 2028 Los Angeles Olympics.
Where the Impact Is Highest
Gender rights advocates and bioethicists have focused on the risk to intersex athletes, particularly those who have never received a diagnosis of their genetic variation. A woman who passes her SRY test without complication will face no disruption. But a woman who unexpectedly fails the test because of an undiagnosed intersex condition would face disclosure of deeply private medical information, the need to navigate an exceptions process while managing her competitive career, and potential public exposure of her genetic status in an environment where prominent athletes who fail these tests, or are suspected of failing them, routinely face public scrutiny.
The 19th emphasized that even the exceptions built into the policy require further tests, medical records, or physician involvement, placing the burden of proof on the player. For a person who has never known she is intersex, receiving that information in the context of a professional sports eligibility process, rather than through a physician-guided discussion, is a significant harm in itself.
What Doctors and Experts Say
Bioethicists and medical geneticists have raised consistent concerns about using genetic testing to determine athletic eligibility. Genetics, they note, does not map cleanly onto athletic performance. An SRY-positive athlete with complete androgen insensitivity syndrome does not have higher circulating testosterone than a typical cisgender woman, does not benefit athletically from her genetic variation, and in some cases may be at a physical disadvantage relative to her peers. Testing for the SRY gene does not test for the one biological variable that most directly relates to athletic performance in endurance and strength sports: circulating androgen levels.
Physicians have also raised concerns about what the policy does not disclose: that genetic testing for sex determination can uncover conditions that athletes have no reason to expect, that test results may not remain private in practice, and that the process of navigating the exceptions pathway could expose players to unwanted disclosure of private health information.
What the Evidence Shows and What It Does Not
The SRY gene test is technically straightforward, typically performed through a cheek swab or blood draw. Detecting the SRY gene is not in dispute as a matter of laboratory science. What is scientifically contested is whether SRY gene status reliably predicts athletic performance advantage. Current evidence does not support a blanket conclusion that SRY-positive athletes, including those with intersex conditions, have performance advantages over SRY-negative athletes. The policy does not include a performance-advantage threshold, and the WTA has not publicly released the scientific basis for concluding that SRY gene status is the appropriate marker for athletic eligibility.
The WTA policy applies universally to all players regardless of whether any competitive fairness concern has been raised about their performance. Whether blanket testing of an entire athlete population to identify a small subset of individuals who may require further scrutiny is proportionate to any documented competitive problem remains a question that medical ethicists, geneticists, and legal scholars are actively debating.
Who Faces the Greatest Risk
The women at greatest risk from the policy are cisgender women with undiagnosed intersex conditions, particularly those with Swyer syndrome, Complete Androgen Insensitivity Syndrome, and other intersex variations involving the SRY gene. These are women who have lived their entire lives as women, who may have never had reason to question their chromosomal status, and who would discover a significant piece of private medical information through a competitive eligibility screening. Transgender women who are already aware of their chromosomal makeup are also affected by the policy.
Symptoms and Warning Signs to Watch For
This article does not address symptoms in the traditional clinical sense. However, women who have had unexplained infertility, amenorrhea, delayed puberty, or unexplained hormonal findings and who compete in professional tennis should be aware that the SRY testing process may reveal intersex conditions that were previously unknown. Consulting a physician before undergoing mandatory genetic testing, rather than receiving results first through a sports organization's process, may provide a more supportive framework for understanding any findings.
What You Can Do Now
For tennis players subject to the policy, understanding the exceptions process, including what documentation may be required and what privacy protections are in place, before submitting to testing is advisable. Organizations including the Trevor Project and GLSEN provide resources on navigating sports policies affecting gender identity. Bioethics and sports law organizations are actively tracking legal challenges to similar policies at other sporting bodies.
For the general public, this policy is an important case study in the limits of genetic testing as a proxy for policy outcomes in competitive sports, and the risks of designing policies that affect an entire population to address concerns about a very small subset.
Cost and Access: What Patients Should Know
The SRY gene test itself is a standard clinical laboratory test that costs between $200 and $500 depending on the facility and whether it is part of a broader genetic panel. In the context of the WTA policy, testing is administered through the sport's governance process. Players seeking to understand their options can consult a physician who specializes in genetics or endocrinology before or after testing.
What Happens Next
Legal challenges to similar gene testing eligibility policies at other sports governing bodies are proceeding in international arbitration. The WTA policy's application to the 2028 Los Angeles Olympics will bring U.S. human rights and discrimination law frameworks into direct engagement with the policy as Olympic qualification approaches. MedicalDaily will track legal, ethical, and scientific developments as they unfold.
The Bottom Line
The WTA's mandatory SRY gene testing policy makes professional women's tennis the first major women's sport to require genetic testing for competition eligibility. The policy's intended targets are transgender women and intersex women with competitive advantages. Its greatest documented risk is to intersex cisgender women who have never known their chromosomal variation and who would encounter that information through a sports eligibility process rather than through clinical care. Whether the genetic test chosen accurately measures the biological variables most relevant to athletic fairness remains scientifically contested
